Boston Scientific Corporation currently sits in a class of its own, boasting a 69.6% implied upside that dwarfs the broader sector average of 18.7%. As of the data snapshot at 00:13 UTC on June 29, 2026, the contrast between the firm’s $44.23 share price and its $75 mean analyst target suggests a significant valuation gap that remains the widest among major industry players.
Price vs targets
Wall Street’s enthusiasm for the stock is supported by a deep bench of 29 analysts, though recent activity indicates a cooling of expectations. Stifel and Jefferies both lowered their price targets in late June, bringing their figures down to $65 and $67, respectively. Despite these downward adjustments, the consensus mean target remains anchored at $75, reflecting a persistent belief in the firm’s long-term trajectory. With a forward P/E ratio of 11.89, the stock looks inexpensive relative to its historical valuation, even as insider sentiment shows a net distribution of shares, with 7 meaningful sells compared to 3 meaningful buys.
| Metric | Value |
|---|---|
| Current Price | $44.23 |
| Mean Target | $75.00 |
| Implied Upside | 69.6% |
| Forward P/E | 11.89x |
| Analyst Count | 29 |
For those tracking the Healthcare sector performance, the spread between BSX and its nearest peers is stark. While the broader group is navigating a period of valuation compression, the gap between market price and analyst consensus for Boston Scientific is unusually wide, highlighting a market disconnect that deserves closer inspection by those monitoring the medical device landscape.
Sector placement
Boston Scientific currently holds the top rank in its peer group for potential upside, a position that sets it apart from other heavy hitters. For context, Zoetis (ZTS) trails significantly with an implied upside of 63%, while Intuitive Surgical (ISRG) and Regeneron (REGN) sit at 39.8% and 31.7%, respectively. The company’s low beta of 0.559 suggests it has acted as a defensive anchor during recent volatility, even as analysts recalibrate their models ahead of the upcoming earnings call on July 29. That spread matters because it highlights that while the sector is seeing broader price target revisions, the market's assessment of Boston Scientific’s growth prospects remains uniquely optimistic compared to the immediate competition.